IP Library Granted Patent US 8,338,185
Granted Patent B2
US 8,338,185 · App. 13/311,366 · Granted Dec 25, 2012

Methods of determining potency of chemically-synthesized oligonucleotides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,338,185
App. No.
13/311,366
Granted
Dec 25, 2012
Kind
B2
Abstract

Provided herein are methods for determining potency of RNAi agents. Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.

Claims (16)

1. A method of determining relative potency of a chemically-synthesized RNAi agent comprising:

forming a first test sample comprising the chemically-synthesized RNAi agent and Ago, wherein the first test sample is not in a cell;

forming a second test sample comprising an RNAi control agent and Ago2, wherein the second test sample is not in a cell; and

measuring the Ago2 activity of the chemically-synthesized RNAi agent and the Ago2activity of the RNAi control agent, wherein the difference in the Ago2 activity of the chemically-synthesized RNAi agent and Ago2 activity of the control RNAi agent indicates potency of the chemically-synthesized RNAi agent relative to the control RNAi agent.

2. The method of claim 1 , wherein the Ago2 is recombinant.

3. The method of claim 1 , wherein the Ago2 is obtained by immunoprecipitation from a cell.

4. The method of claim 2 , wherein the cell is made to over-express the Ago2 protein.

5. The method of claim 1 , wherein the degree of binding is measured by measuring an amount of chemically-synthesized RNAi agent bound to the Ago2.

6. The method of claim 1 , wherein the chemically-synthesized RNAi agent is an oligonucleotide.

7. The method of claim 6 , wherein the oligonucleotide is from about 15 to about 27 nucleotides in length.

8. The method of claim 6 , wherein the oligonucleotide comprises a complementary strand from about 15 to about 27 nucleotides in length.

9. The method of claim 6 , wherein the oligonucleotide is an antisense oligoribonucleotide.

10. The method of claim 6 , wherein the oligonucleotide comprises at least one sugar-modified nucleotide.

11. The method of claim 10 , wherein the sugar-modified nucleotide is a 2′ substituted nucleotide.

12. The method of claim 6 , wherein the oligonucleotide comprises at least one modified internucleoside linkage.

13. The method of claim 12 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.

Assignments (1)
CHANGE OF NAME Recorded Jun 28, 2017
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 043029/0365 →